SanBio : Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
September 10, 2020 at 05:25 am EDT
Share
September 10, 2020
Company name:
SanBio Co., Ltd.
Representative:
Keita Mori, Representative Director and
President
(TSE Mothers Code: 4592)
Contact:
Yoshihiro Kakutani, Corporate Officer of
Management Administration
(TEL. +81-3-6264-3481)
Determination of Terms and Conditions of Stock Options
(Share Acquisition Rights)
SanBio Company Limited (hereafter, "the Company") hereby announces that the pending terms and conditions of the share acquisition rights (the "Share Acquisition Rights"), to be issued as part of the Company's stock option program pursuant to the Board of Directors' resolution dated August 26, 2020, have been determined as follows:
1. Total Number of Share Acquisition Rights
56,000 units (one common share of the Company per one unit of Share Acquisition Right)
Type and Number of Shares Subject to Share Acquisition Rights 56,000 shares of common stock in the Company
Value of the Asset to be Contributed upon Exercise of Share Acquisition Rights 1,488 yen per one unit of Share Acquisition Right (1,488 yen per share)
Persons to whom Share Acquisition Rights are Allocated, the Number of such persons, and the Number of Share Acquisition Rights Allocated
Persons to whom Share
Number of such Persons
Number of Share Acquisition Rights
Acquisition Rights are
Allocated
Allocated
Employees of the Company
1
1,000 units
Employees of the
3
55,000 units
Company's Subsidiary
End
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
SanBio Co. Ltd. published this content on 10 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2020 09:24:01 UTC
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).